CD38 and AL amyloidosis: On March 2021, idecabtagene vicleucel (ABECMATM) from Bristol Myers Squibb was approved as the first cell-based immunotherapy for adult patients with r/r multiple myeloma after four or more preceded lines of therapy, including an anti-CD38 monoclonal antibody, an immunomodulator, and a proteasome inhibitor (Munshi et al., 2021).